跳到主要导航
跳到搜索
跳到主要内容
Pure University (For Demo Only) 国内
帮助和常见问题
English
中文
国内
简介
研究单位
科研成果
设备
数据集
活动
奖项
影响
项目
新闻 / 媒体
按专业知识、名称或附属进行搜索
联系专家
查看 Scopus 资料
Kim Youra
Associate Professor
Dalhousie University
,
Decision Sciences
电子邮件
KY855300
dal
ca
网站
https://www.scopus.com/authid/detail.url?authorId=56605855300
h-index
h10-index
h5-index
703
引用
14
H-指数
根据储存在 Pure 的刊物以及来自 Scopus 的引用文献数量计算
703
引用
14
H-指数
根据储存在 Pure 的刊物以及来自 Scopus 的引用文献数量计算
43
引用
4
H-指数
根据储存在 Pure 的刊物以及来自 Scopus 的引用文献数量计算
2015
2022
每年的科研成果
综述
指纹
网络
科研成果
(18)
新闻 / 媒体
(2)
相似简介
(6)
指纹
深入其中 Kim Youra 为活跃的研究主题。这些主题标签来自此人的成果。它们共同形成唯一的指纹。
分类
加权
按字母排序
Keyphrases
Oncolytic Virus
90%
Cancer Immunotherapy
50%
Granulocytic
45%
Proteomic Response
45%
Oncolytic Vaccine
45%
Quantitative Proteome
45%
Antitumor
45%
Antiviral Immunity
45%
Oncolytic Virotherapy
45%
Surfen
45%
Autophagic
45%
Binding Agent
45%
CD8+ T Cell Immunity
45%
Oncolytic Viral Therapy
45%
Glitters
45%
MHC-I Peptides
45%
Isobaric Tagging
45%
Relative Quantitation
45%
Ligand Dynamics
45%
Peptidome
45%
Virus-associated Cancer
45%
T-cell Reactivity
45%
Immunosuppression
45%
COVID-19 Pandemic
45%
In Vivo Proteomics
45%
COVID-19
45%
Cancer Metabolism
45%
Epigenetic Silencing
45%
Biliary Tract
45%
Gr-1
45%
Cholangiocarcinoma
45%
Repurposing
45%
Immunosurveillance
45%
Primary Biliary Cholangitis
35%
Reference Proteomes
33%
Tumor Immunity
32%
POU5F1
27%
Chondroitin Sulfate Proteoglycans
22%
Oncolytic Adenovirus
22%
Novel Class
22%
Anticancer Therapeutic Agent
22%
Anticancer Therapy
22%
Allotype
22%
Cancer-related
22%
M2-like
18%
Ly6G
18%
Viral Clearance
18%
Natural Infection
15%
Immunotherapy Strategy
15%
CD8+ T Cells
15%
Immunology and Microbiology
Oncolytic Virus
100%
Oncolytic Reovirus
90%
Dendritic Cell
45%
Remyelinization
45%
Chondroitin Sulfate Proteoglycan
45%
Macrophage Colony-Stimulating Factor
45%
Antiviral Immunity
45%
Tumor-Associated Immunosuppression
45%
Major Histocompatibility Complex
45%
Pyruvate Dehydrogenase
45%
Dynamics
45%
Reoviridae
45%
Cancer Immunotherapy
45%
Vaccine Efficacy
45%
Myeloid
45%
Cytotoxic T-Cell
45%
Tumor Antigen
45%
Primary Biliary Cirrhosis
45%
Hepatobiliary System
45%
Cancer Cell
31%
Viral Clearance
27%
Immunotherapy
26%
Allotype
22%
Immune Response
21%
T Cell
19%
Primary Sclerosing Cholangitis
19%
Aggrecan
18%
Co-Stimulatory Molecule
12%
Cholangiocyte
12%
Immunosuppression
11%
Myeloid-Derived Suppressor Cell
11%
Hematopoietic Stem Cell
11%
Cell Migration
11%
Monospecific Antibody
11%
Cell Survival
11%
Adaptive Immune System
11%
T Cell Proliferation
11%
Immune Escape
11%
Monocyte Chemotactic Protein 1
9%
CCL2
9%
Neurocan
9%
Corpus Callosum
9%
Macrophage Inflammatory Protein 1beta
9%
Macrophage Inflammatory Protein 1alpha
9%
CCL3
9%
CCL5
9%
Versican
9%
MHC Class I
9%
Cell Surface
9%
Cell Cycle
9%
Medicine and Dentistry
Remyelination
45%
Proteochondroitin Sulfate
45%
Proteoglycan
45%
Tumor-Associated Immunosuppression
45%
Cellular Immunity
45%
Cancer Immunotherapy
45%
Pyruvate Dehydrogenase Kinase
45%
COVID-19
45%
Severe Acute Respiratory Syndrome Coronavirus 2
45%
Myeloid Cell
45%
Oncolytic Reovirus
45%
Cytotoxic T-Cell
45%
Reoviridae
45%
Nicotinamide Adenine Dinucleotide
45%
Lysophosphatidylcholine
36%
Neoplasm
22%
Oncolytic Virus
22%
Syndecan 4
18%
Aggrecan
18%
Proteoheparan Sulfate
18%
RANTES
18%
Infection
15%
Pyruvate Dehydrogenase
12%
Tumor Initiation
12%
Co-Stimulatory Molecule
12%
Tumor Microenvironment
11%
Hematopoietic Stem Cell
11%
Immunosuppressive Treatment
11%
Immunotherapy
11%
Myeloid-Derived Suppressor Cell
11%
T Cell Proliferation
11%
Cell Migration
11%
Epileptic Absence
11%
Antibodies
11%
Cell Survival
11%
Cancer Cell
11%
Neurocan
9%
Agrin
9%
Perlecan
9%
Inducible Nitric Oxide Synthase
9%
Bone Marrow Derived Macrophage
9%
Corpus Callosum
9%
Macrophage Inflammatory Protein 1alpha
9%
Versican
9%
Macrophage Inflammatory Protein 1beta
9%
Epitope
6%
Dichloroacetic Acid
6%
Bisulfite
6%
Chemokine Receptor
6%
Pyrosequencing
6%
